(2R)-1,4-ditert-butyl-2-methylpiperidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (2R)-1,4-ditert-butyl-2-methylpiperidine
• 化学式: C₁₄H₂₉N
• 分子量: 211.39
• InChiKey: WVGMSEJDODWFPO-JHJMLUEUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE
  申请人：GENZYME CORPORATION

  公开号：US20200102324A1

  公开（公告）日：2020-04-02

  Described herein is a compound of Formula (I), and pharmaceutically acceptable salts thereof. Also described herein are compositions and the use of such compositions in methods of treating a variety of diseases and conditions, in particular Krabbe's Disease (KD) and Metachromatic leukodystrophy (MLD).

  本文描述了一种化合物，其化学式为（I），以及其药用盐。本文还描述了这些组合物以及在治疗各种疾病和症状的方法中使用这些组合物，特别是克拉贝氏病（KD）和间染色质白质脑病（MLD）。
• COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
  申请人：PLEXXIKON INC.

  公开号：US20140128390A1

  公开（公告）日：2014-05-08

  Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and mutant c-kit protein kinases.

  本文描述了对c-kit蛋白激酶或携带任何突变的突变c-kit蛋白激酶起作用的化合物，以及制备和使用这种化合物治疗与c-kit蛋白激酶和突变c-kit蛋白激酶的异常活性相关的疾病和病状的方法。
• Compounds and methods for kinase modulation, and indications therefor
  申请人：Plexxikon Inc.

  公开号：US10227357B2

  公开（公告）日：2019-03-12

  Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and mutant c-kit protein kinases.

  本文描述了对具有任何突变的 c-kit 蛋白激酶或突变 c-kit 蛋白激酶具有活性的化合物，以及制造和使用此类化合物治疗与 c-kit 蛋白激酶和突变 c-kit 蛋白激酶异常活性相关的疾病和病症的方法。
• Cytotoxin and conjugate, uses of same and preparation method therefor
  申请人：SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.

  公开号：US11207420B2

  公开（公告）日：2021-12-28

  Provided is a method for modifying a chimeric antigen receptor-modified T cell (CAR-T cell). The method comprises expressing an SCFV-CDS TM-4-1BB-CD3ζ molecule in a T cell. The CAR-T cell prepared using the method can specifically recognize and bind to a tumor cell with elevated expression of a ROBO1 protein, and can be used to prevent and treat a corresponding tumor-related disease.

  本文提供了一种修饰嵌合抗原受体修饰 T 细胞（CAR-T 细胞）的方法。该方法包括在 T 细胞中表达 SCFV-CDS TM-4-1BB-CD3ζ 分子。使用该方法制备的 CAR-T 细胞可特异性识别并结合 ROBO1 蛋白表达增高的肿瘤细胞，并可用于预防和治疗相应的肿瘤相关疾病。
• CYTOTOXIN AND CONJUGATE, USES OF SAME AND PREPARATION METHOD THEREFOR
  申请人：SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.

  公开号：US20200179529A1

  公开（公告）日：2020-06-11

  Provided is a method for modifying a chimeric antigen receptor-modified T cell (CAR-T cell). The method comprises expressing an SCFV-CDS TM-4-1BB-CD3ζ molecule in a T cell. The CAR-T cell prepared using the method can specifically recognize and bind to a tumor cell with elevated expression of a ROBO1 protein, and can be used to prevent and treat a corresponding tumor-related disease.